A Study to Compare Oral Absorption of YM060 Between Orally-disintegrating Tablet and Conventional Tablet Under With Water Intake
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
20 Years to 44 Years (Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
healthy assessed by the principal investigator or sub-investigators
non-smoking or stop smoking at least 90 days before the study
body weight: over 50.0kg and less than 80.0kg
body mass index (BMI): over 17.6 and less than 26.4
participated in another clinical trial (including a post-marketing clinical study) within 120 days before the study
donated 400mL of whole blood within 90 days, 200mL of whole blood within 30 days or blood components within 14 days before the study
received any drugs within 7 days before the study or going to receive any drugs
deviance from normal range in vital signs (blood pressure, pulse rate, and body temperature) or 12-lead ECG
deviance from normal range in lab-tests
history of drug allergy
history or current diagnosis of stomach, small intestine or large intestine diseases
history or current diagnosis of inflammatory bowel disease (Crohn's disease or colitis ulcerative)
history or current diagnosis of colitis ischemic
history or current diagnosis of hepatic diseases
history or current diagnosis of cardiovascular diseases
history or current diagnosis of respiratory diseases